title: Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
abstract: The mouse-virulent RH strain of Toxoplasma gondii is generally considered to have lost its cyst-forming capacity, and conversion of RH tachyzoites into cysts in non-immune mice has previously been shown exclusively following early treatment with sulfadiazine (SDZ). We here describe the development of tissue cysts in mice infected with RH strain parasites and treated with atovaquone (ATO) combined with pyrrolidine dithiocarbamate (PDTC). Groups of Swiss-Webster mice infected intraperitoneally (i.p.) with 10(2) RH tachyzoites were treated with 5, 25 and 100 mg of ATO/kg per day alone or combined with PDTC at 250 mg/kg per day from day 1 postinfection (p.i.) for 14 days. A total of 19 mice survived the 6-week observation period. Of these, brain cysts were recovered in nine (47%), with burdens ranging from 50 to 3120 (mean +/- S.D. = 622 +/- 963). All cyst-harboring mice had high specific IgG antibody levels (1:10,240-1:40,960, corresponding to 500-2000 IU/ml), as did one mouse in which cysts were not demonstrated, which was therefore included in the group of mice with residual infection. Bioassay performed to test the infectivity of these cysts produced acute lethal toxoplasmosis following i.p. inoculation in all instances (100%), and importantly, following peroral inoculation in four (29%). The recovered tachyzoites were highly infectious. In addition, significantly elevated interferon gamma (IFN-gamma) in the treated mice which developed residual infection compared with any group of infection-free (treated or subinoculated) mice, indicates immunological control of the parasite in the latent form. In conclusion, early treatment of mice infected with T. gondii RH tachyzoites with ATO and PDTC induces conversion into tissue cysts, thus providing a new model for studying the mechanism(s) of T. gondii stage conversion.
authors.affiliation: Toxoplasmosis Research Laboratory, Department of Medical Parasitology, Institute for Medical Research, Dr. Subotića 4, P.O. Box 102, 11129 Belgrade, Serbia and Montenegro. olgicadj@imi.bg.ac.yu
authors.forename: Olgica
authors.initials: O
authors.lastname: Djurković-Djaković
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Nikolić
authors.forename: Branko
authors.initials: B
authors.lastname: Bobić
authors.forename: Ivana
authors.initials: I
authors.lastname: Klun
authors.forename: Anastasija
authors.initials: A
authors.lastname: Aleksić
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D053626:Atovaquone; D001921:Brain / Q000469:parasitology* / Q000473:pathology; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use*; D033661:Oocysts / Q000302:isolation & purification*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013859:Thiocarbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D014122:Toxoplasma / Q000254:growth & development / Q000302:isolation & purification / Q000472:pathogenicity*; D014123:Toxoplasmosis / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology
chemical_list: D000981:Antiprotozoal Agents; D009285:Naphthoquinones; D011759:Pyrrolidines; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D053626:Atovaquone